[Department Memorandum No. 2021- 0317] Non-inclusion of Pazopanib as a Second-line Treatment for Metastatic Soft Tissue (mSTS) Sarcoma in the Philippine National Formulary (PNF)
[Department Circular No. 2021- 0273] HTAC Issuance on Acceptance and processing of Health Technologies under Monitored Release with Phase IV Trial Data
[Department Memorandum No. 2021- 0294] Non-inclusion of Lapatinib in the Philippine National Formulary
[Department Memorandum No. 2021- 0264] Health Technology Assessment Council’s (HTAC) Recommendation on COVID-19 Vaccine Moderna
[Department Memorandum No. 2021- 0252] Health Technology Assessment Council’s (HTAC) Recommendations on RT-PCR and Rapid Antigen Testing for COVID-19
[Department Memorandum No. 2021- 0242] inclusion of Nicotine replacement therapy (NRT) and Varenicline in the Primary Care Formulary
[Department Memorandum No. 2021- 0227] Health Technology Assessment Council’s (HTAC) Recommendations on COVID-19 heath technologies
[Department Memorandum No. 2021- 0199] Health Technology Assessment Council’s (HTAC) Recommendations on COVID-19 heath technologies
